glp-1 parkinson's disease GLP-1/GIP dual agonist tirzepatide alleviates mice model of by promoting mitochondrial homeostasis How a 'blockbuster' treatment for
Description
In clinical practice, the degree of weight loss with lifestyle intervention is only moderate, and the success rate 2 years after onset of an intervention is low ( 40% reached a category below the obesity threshold [14]
Important safety information includes a boxed warning for risk of thyroid C-cell tumors and contraindications in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Metformin is administered orally and has been available for decades
Easy and fast
The relationship feels collaborative
JAMA , 333 (8), 652655.
